The CYP3A4* 1B allele increases risk for small cell lung cancer: Effect of gender and smoking dose

Pharmacogenetics

Volumn 13, Issue 10, 2003, Pages 607-618

  Dally, Heike ^a   Edler, Lutz ^a   Jäger, Birgit ^a   Schmezer, Peter ^a   Spiegelhalder, Bertold ^a   Dienemann, Hendrik ^b   Drings, Peter ^b   Schulz, Volker ^b   Kayser, Klaus ^b   Bartsch, Helmut ^a   Risch, Angela ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CYP3A; Genetic polymorphism; LightCycler; Lung cancer susceptibility; Small cell lung cancer

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; GENDER; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING; STATISTICAL SIGNIFICANCE; TOBACCO; ADENOCARCINOMA; ADOLESCENT; ALLELE; CASE CONTROL STUDY; COMPARATIVE STUDY; DOSE RESPONSE; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; MIDDLE AGED; RISK FACTOR; SEX RATIO; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA;

NICOTIANA TABACUM;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RISK FACTORS; SEX DISTRIBUTION; SMOKING;

EID: 0142188773     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200310000-00004     Document Type: Article

References (56)

1. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39:1-17.
2. Gibson GG, Plant NJ, Swales KE, Ayrton A, El Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002; 32:165-206.
3. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999; 369:11-23.
4. Yamazaki H, Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 1997; 346:161-169.
5. Shimada T, Martin MV, Pruess-Schwartz D, Marnett LJ, Guengerich FP. Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res 1989; 49:6304-6312.
6. El Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001; 29:1499-1504.
7. Roberts-Thomson SJ, McManus ME, Tukey RH, Gonzalez FF, Holder GM. The catalytic activity of four expressed human cytochrome P450s towards benzo[a]pyrene and the isomers of its proximate carcinogen. Biochem Biophys Res Commun 1993; 192:1373-1379.
8. Shou M, Krausz KW, Gonzalez FJ, Gelboin HV. Metabolic activation of the potent carcinogen dibenzo[a, l]pyrene by human recombinant cytochromes P450, lung and liver microsomes. Carcinogenesis 1996; 17:2429-2433.
9. Patten CJ, Smith TJ, Friesen MJ, Tynes RE, Yang CS, Murphy SE. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N′- nitrosonornicotine alpha-hydroxylation by human liver microsomes. Carcinogenesis 1997; 18:1623-1630.
10. Piipari R, Savela K, Nurminen T, Hukkanen J, Raunio H, Hakkola J, et al. Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int J Cancer 2000; 86:610-616.
11. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59:386-392.
12. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281:1349-1355.
13. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000; 260: 13-23.
14. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11:111-121.
15. Mace K, Bowman ED, Vautravers P, Shields PG, Harris CC, Pfeifer AM. Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer 1998; 34:914-920.
16. Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, et al. Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 1997; 16:242-249.
17. Van Vleet TR, Klein PJ, Coulombe RA, Jr. Metabolism and cytotoxicity of aflatoxin b1 in cytochrome p-450- expressing human lung cells. J Toxicol Environ Health A 2002; 65:853-867.
18. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294.
19. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10:373-388.
20. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993; 218:585-595.
21. Amirimani B, Walker AH, Weber BL, Rebbeck TR. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999; 91:1588-1590.
22. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999; 259:201-205.
23. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, et al. The CYP3A4* 1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002; 12:355-366.
24. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12:121-132.
25. Deitz A, Swoyer J, Acs G, Gunasegaram S, Rebbeck T. Association of CYP3A4* 1B and pathological characteristics of breast tumors [Abstract]. Proc AACR 2001; 42:154.
26. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90:1225-1229.
27. Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep 2002; 9:653-655.
28. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.
29. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62:162-172.
30. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.
31. van Schaik RH, van dH, I, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48:1668-1671.
32. Wojnowski L, Hustert E, Klein K, Goldammer M, Haberl M, Kirchheiner J, et al. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 2002; 94:630-631.
33. Muscat JE, Wynder EL. Lung cancer pathology in smokers, ex-smokers and never smokers. Cancer Lett 1995; 88:1-5.
34. Wikman H, Thiel S, Jäger B, Schmezer P, Spiegelhalder B, Edler L, et al. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 2001; 11:157-168.
35. Risch A, Wikman H, Thiel S, Schmezer P, Edler L, Drings P, et al. Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics 2001; 11:757-764.
36. Wikman H, Risch A, Klimek F, Schmezer P, Spiegelhalder B, Dienemann H, et al. hOGG1 polymorphism and loss of heterozygosity (LOH): significance for lung cancer susceptibility in a Caucasian population. Int J Cancer 2000; 88:932-937.
37. Dally H, Gassner K, Jäger B, Schmezer P, Spiegelhalder B, Edler L, et al. Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer 2002; 102:530-535.
38. Wittwer CT, Herrmann MG, Gundry CN, Elenitoba-Johnson KS. Real-time multiplex PCR assays. Methods 2001; 25:430-442.
39. Liu TC, Lin SF, Chen TP, Chang JG. Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep 2002; 9:327-329.
40. Breslow NE, Day NE. Statistical methods in cancer research, vol. I. The analysis of case-control studies. Lyon, France: IARC Sci Publ; 1980, pp. 5-338.
41. Kayser K. Analytical lung pathology. Berlin; New York: Springer-Verlag; 1992.
42. Brambilla C, Brambilla E. Lung tumors: fundamental biology and clinical management. New York: Marcel Dekker, Inc.; 1999.
43. Shih PS and Huang JD. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002; 30:1491-1496.
44. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293:489-493.
45. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002; 61:586-594.
46. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12:725-733.
47. Huang Z, Guengerich FP, Kaminsky LS. 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis 1998; 19:867-872.
48. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther 1993; 57:237-257.
49. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K. Steroid hormone hydroxylase specificities of 11 cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991; 290:160-166.
50. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996; 93:3294-3296.
51. Kahan BD, Kramer WG, Wideman CA, Frazier OH, Lorber MI, Williams C, et al. Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. Transplant Proc 1986; 18:115-119.
52. Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E Jr, Ferry JJ, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54:402-414.
53. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000; 68:130-142.
54. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88:183-192.
55. Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 2000; 30:153-160.
56. Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001; 10:209-216.